Search Results
Nov 18, 2025, 15:20 ET The Inner Circle acknowledges, Cindy Barnes as a Pinnacle Professional Member Inner Circle of Excellence
successful transactions. Cindy is a licensed Realtor and holds advanced designations including Certified Residential Specialist (CRS) and Accredited Buyer's Representative (ABR). She is also an active member of the National Association of Realtors, staying connected to industry standards
More news about: The Inner Circle
Nov 18, 2025, 12:47 ET AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
site reactions, constipation, diarrhea, cytokine release syndrome (CRS), pneumonia, COVID-19 and fever. The most common Grade 3 to 4 laboratory abnormalities (≥ 10%) were decreased neutrophil count, lymphocyte count, and platelets. CRS occurred in 24% of patients at the recommended 3 step-up dosage schedule,
More news about: AbbVie
Nov 18, 2025, 04:00 ET Delta Cargo implements IBS Software's full iCargo Solution for future ready transformation
management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty, and distribution. For the tour & cruise industry, IBS
More news about: IBS Software
Nov 17, 2025, 10:27 ET PRV111, in Development as the First Non-Surgical Therapy for Early-Stage Non-Invasive Oral Cancer and High-Grade Dysplasias, Meets Its Primary Efficacy Endpoint in Ongoing Phase 2/3 Trial
biopsy-confirmed non-invasive oral cancers or high-grade dysplasia received a single cycle of PRV111. Eleven patients achieved centrally confirmed pathologic CRs; the twelfth patient was down staged to low-grade dysplasia, eliminating the need for surgery. All treated lesions resolved, and mucosal surfaces regenerated
More news about: Privo Technologies
Nov 11, 2025, 08:00 ET Dominari 2025 Revenue Surges 703% in First Nine Months, Balance Sheet Strengthens Significantly
the principal invested. You can check the background of Dominari Securities LLC and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Nov 11, 2025, 07:30 ET BTQ Exercises Option to Acquire QPerfect, a Leading Neutral Atom Computing Company, Strengthening BTQ as a Fully Integrated Quantum Company
Stage B of DARPA's Quantum Benchmarking Initiative (QBI)). QPerfect also maintains research and licensing agreements with institutional partners like CRS4 in Italy and industrial partners, including Quobly in France, reinforcing commercial traction and supporting recurring software licensing and collaborative
More news about: BTQ Technologies Corp.
Nov 07, 2025, 09:00 ET CREATE Medicines Announces Positive First-in-Human Results for MT-302
release syndrome observed in 51.9% of participants with kinetics consistent with tumor target engagement. There were no events of grade 3 or higher CRS. Maximum tolerated dose: 0.10 mg/kg without steroid premedication. One Grade 4 ICANS event was observed at the highest dose
More news about: CREATE Medicines, Inc.
Nov 04, 2025, 01:00 ET IBS Software announces Strategic Collaboration Agreement with Amazon Web Services to redefine airline retailing
management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty, and distribution. For the tour & cruise industry, IBS
More news about: IBS Software
Nov 03, 2025, 13:31 ET Recordati Rare Diseases to Share New Data at the American Society of Hematology (ASH) Meeting
in the treatment of patients with CAD or CAS; and a prospective evaluation of siltuximab in the prevention or treatment of cytokine release syndrome (CRS) after CAR T-cell therapy.
More news about: Recordati
Nov 03, 2025, 09:15 ET CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
No dose-limiting toxicities (DLT), treatment discontinuations, or deaths were observed. Four patients experienced Grade 1 cytokine release syndrome (CRS), all of which resolved within 2-10 days. Previously, in October 2025, CARsgen announced preliminary clinical data for CT0596
More news about: CARsgen Therapeutics
Nov 03, 2025, 09:00 ET Cowbell Unveils Brand Refresh: The Sound Approach to Risk for the New AI Era
in commercial and specialty lines, including cyber, technology errors and omissions, and management liability. Through Cowbell Resiliency Services (CRS)—an independent cybersecurity advisory arm—policyholders gain access to Digital Forensics and Incident Response (DFIR) services as well as proactive solutions,
More news about: Cowbell Cyber, Inc.
Oct 31, 2025, 07:49 ET AbbVie Reports Third-Quarter 2025 Financial Results
received at least one prior line of systemic therapy. Results from the study demonstrated that the incidence and severity of cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS) following treatment with epcoritamab were consistent with previous epcoritamab studies in
More news about: AbbVie
Oct 30, 2025, 05:00 ET IBS Software Appoints Abha Dogra as Chief Product Officer
management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty, and distribution. For the tour & cruise industry, IBS
More news about: IBS Software
Oct 28, 2025, 19:00 ET PTS to Launch Japan-Origin Bitcoin Mining Investment Product via Republic Platform Under U.S. Regulation
and Form CRS
More news about: Pivotal Trend Service Co., Ltd.
Oct 28, 2025, 19:00 ET PTS to Launch Japan-Origin Bitcoin Mining Investment Product via Republic Platform Under U.S. Regulation
and Form CRS
More news about: Pivotal Trend Service Co., Ltd.
Oct 28, 2025, 17:31 ET CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
achieving complete remission after other treatments have failed. Nonetheless, CAR-T therapy carries potential risks, including Cytokine Release Syndrome (CRS) and neurological side effects, requiring vigilant monitoring by trained healthcare professionals throughout the treatment process.
More news about: DelveInsight Business Research, LLP
Oct 28, 2025, 05:00 ET Thai Airways invests in Digital Loyalty Transformation with IBS Software's iLoyal Platform
management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty, and distribution. For the tour & cruise industry, IBS
More news about: IBS Software
Oct 27, 2025, 18:21 ET Taxbit Appoints Former OECD Advisor Colby Mangels as Global Head of Government Solutions
leading role in developing the Crypto-Asset Reporting Framework (CARF) and the most recent amendments to the Common Reporting Standard (CRS), as well as in leading peer reviews of jurisdictions' compliance with these international transparency standards. He also contributed to the Financial
More news about: Taxbit
Oct 26, 2025, 21:00 ET Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy.
More news about: Antengene Corporation Limited
Oct 23, 2025, 09:00 ET Cowbell Announces Strategic Appointments to Advance Mid-Market and Claims Leadership
in commercial and specialty lines, including cyber, technology errors and omissions, and management liability. Through Cowbell Resiliency Services (CRS)—an independent cybersecurity advisory arm—policyholders gain access to Digital Forensics and Incident Response (DFIR) services as well as proactive solutions
More news about: Cowbell Cyber, Inc.
Oct 22, 2025, 07:39 ET Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
respectively. Safety: Cytokine release syndrome (CRS) occurred in 88.9% of patients, primarily grade 1-2. Only one patient developed grade 3 or higher CRS, which rapidly recovered with intensive management. One patient developed grade 3 immune effector
More news about: IASO Bio
Oct 20, 2025, 20:33 ET MTC, ABAG Release Draft of New Long-Range Plan for Bay Area
al (415) 778-6757. Para telecomunicaciones para personas sordas y discapacitadas, favor de llamar al 711, el Servicio de Retransmisión de California (CRS) para TTY/VCO/HCO a Voz o para Voz a TTY/VCO/HCO al (800) 855-3000 y pedir que lo retrasmitan al (415) 778-6700. 您是否需要口譯或任何其他
More news about: Metropolitan Transportation Commission
Oct 19, 2025, 21:00 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
demonstrated durable response and has been on the study for over 22 months. To date, the study has observed three CRs, one from each of the three forementioned cohorts (two dose cohorts among CLDN18.2 mid/high expressors and the cohort of low/ultra low CLDN18.2 expressors).
More news about: Antengene Corporation Limited
Oct 19, 2025, 20:15 ET CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
51.3% to 96.1%. All patients developed Grade 1 or 2 cytokine release syndrome (CRS) after the first satri-cel infusion. For the second infusion administered in one patient, grade 3 CRS accompanied by hypotension was observed, which was resolved within three days following tocilizumab
More news about: CARsgen Therapeutics
Oct 19, 2025, 02:00 ET Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
(proteasome inhibitor, immunomodulatory agent, and CD38 monoclonal antibody). The patient developed Grade 1 CRS, Grade 4 neutropenia, and thrombocytopenia following lymphodepletion and CAR-T cell infusion. The CRS and cytopenias were resolved after treatment with tocilizumab and other supportive measures. CAR-T
More news about: CARsgen Therapeutics